Biotech Stocks Poised for Recovery as Rate Cuts Loom
Source: www.tradingview.com
Biotech stocks have struggled recently, mainly due to high interest rates making it difficult for companies to fund their research and trials. However, the outlook could soon change with the Federal Reserve expected to cut rates. Biotech stocks typically perform better in a low-rate environment, and we're already seeing signs of recovery, with the SPDR S&P Biotech ETF (XBI) outpacing the broader market over the past three months.
Technically speaking, there are also bullish signals on the longer-term XBI monthly chart. The EMAs are in a bullish formation, and the underlying indicators suggest strong momentum is present. This technical strength adds to the optimism that the sector is poised for further gains.
The sector's fundamentals are improving as well, with fewer companies running at a loss. Even large-cap stocks like Gilead Sciences are showing signs of recovery, as analysts recognise potential in their current businesses and future projects.
If rates do drop, the biotech sector could continue to build momentum, providing a much-needed boost for the healthcare industry and potentially offering a positive tailwind for the broader market too.
Image by fernando zhiminaicela from Pixabay
Russell Shor
Senior Market Strategist
Russell Shor is a Senior Market Strategist at FXCM, having been promoted to the role in 2025 in recognition of his depth of insight and consistent delivery of high-impact market analysis. He originally joined FXCM in October 2017 as a Senior Market Specialist.
Russell holds an Honours Degree in Economics from the University of South Africa, is a certified FMVA®, and a full member of the Society of Technical Analysts (UK). With over 20 years of experience in financial markets, his work is renowned for its clarity, precision, and strategic value across asset classes.
These materials constitute marketing communication and do not take into consideration your personal circumstances, investment experience or current financial situation. The content is provided as general market commentary and should not be construed as containing any type of investment advice, investment recommendation and/or a solicitation for any investment transactions. This market communication does not imply or impose an obligation on you to perform an investment transaction and/or purchase investment products or services. These materials have not been prepared in accordance with legal requirements designed to promote the independence of investment research and are not subject to any prohibition on dealing ahead of the dissemination of investment research.
FXCM, and any of its Affiliates, shall not in any way be liable to you for any inaccuracies, errors or omissions, regardless of cause, in the content of these materials, or for any damages (whether direct or indirect) which may arise from the use of such materials, services and their content. Consequently, any person acting on them does so entirely at their own risk. Please ensure that you read and understand our Full Disclaimer and Liability provision concerning the foregoing Information, which can be accessed here.